Head-to-head evidence
PEX168 vs XW014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
PEX168
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT02477969 · Phase 3 · status unknown
This was a randomized, triple-blind, placebo-controlled trial with 587 participants, testing PEX168 against placebo, both added to metformin, using change in HbA1c as the primary measure. A published report of the trial's results describes the primary endpoint as met, with substantially more PEX168 patients than placebo patients reaching HbA1c targets at 24 weeks.
XW014
Developed by Sciwind Biosciences
NCT05579314 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse events and routine safety measurements rather than a diabetes outcome such as blood sugar control, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PEX168's landscape · XW014's landscape